Teva Pharmaceutical Industries PE Ratio 2006-2018 | TEVA

Current and historical p/e ratio for Teva Pharmaceutical Industries (TEVA) from 2006 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Teva Pharmaceutical Industries PE ratio as of April 23, 2019 is 5.16.
Teva Pharmaceutical Industries PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2019-04-23 14.91 0.00
2018-12-31 15.42 $-2.33 0.00
2018-09-30 21.54 $-10.89 0.00
2018-06-30 24.32 $-10.10 0.00
2018-03-31 17.09 $-15.80 0.00
2017-12-31 18.95 $-16.26 0.00
2017-09-30 17.50 $-5.95 0.00
2017-06-30 32.86 $-6.12 0.00
2017-03-31 31.37 $0.02 1568.54
2016-12-31 35.10 $0.07 501.38
2016-09-30 44.14 $1.72 25.66
2016-06-30 47.88 $1.49 32.13
2016-03-31 50.67 $1.92 26.39
2015-12-31 61.79 $1.82 33.95
2015-09-30 52.84 $2.07 25.53
2015-06-30 55.04 $2.97 18.53
2015-03-31 57.70 $3.21 17.97
2014-12-31 52.94 $3.56 14.87
2014-09-30 49.21 $3.21 15.33
2014-06-30 47.68 $3.03 15.74
2014-03-31 47.72 $1.63 29.28
2013-12-31 35.94 $1.50 23.96
2013-09-30 33.63 $1.42 23.69
2013-06-30 34.66 $0.49 70.74
2013-03-31 34.85 $2.01 17.34
2012-12-31 32.57 $2.24 14.54
2012-09-30 35.94 $2.44 14.73
2012-06-30 34.05 $3.56 9.56
2012-03-31 38.70 $3.21 12.06
2011-12-31 34.51 $3.08 11.21
2011-09-30 31.69 $3.36 9.43
2011-06-30 40.86 $3.48 11.74
2011-03-31 42.35 $3.72 11.38
2010-12-31 43.81 $3.67 11.94
2010-09-30 44.18 $3.24 13.64
2010-06-30 43.40 $2.81 15.44
2010-03-31 52.51 $2.51 20.92
2009-12-31 46.64 $2.23 20.91
2009-09-30 41.87 $0.93 45.02
2009-06-30 40.77 $0.98 41.60
2009-03-31 37.12 $1.05 35.35
2008-12-31 34.99 $0.72 48.60
2008-09-30 37.56 $2.29 16.40
2008-06-30 37.49 $2.16 17.36
2008-03-31 37.62 $2.14 17.58
2007-12-31 37.78 $2.38 15.87
2007-09-30 36.08 $2.24 16.11
2007-06-30 33.40 $2.34 14.28
2007-03-31 30.25 $2.30 13.15
2006-12-31 25.06 $0.48 52.22
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $14.948B $18.854B
TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions. Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $46.653B 8.40
Mylan (MYL) United Kingdom $13.786B 5.83
Bausch Health Cos (BHC) Canada $8.017B 5.70
Dr Reddy's Laboratories (RDY) India $6.725B 26.82
Supernus Pharmaceuticals (SUPN) United States $1.903B 17.66
Mallinckrodt Public Limited Company (MNK) United Kingdom $1.487B 2.42
Amphastar Pharmaceuticals (AMPH) United States $0.962B 88.91
Homology Medicines (FIXX) United States $0.819B 0.00
CymaBay Therapeutics (CBAY) United States $0.717B 0.00
Voyager Therapeutics (VYGR) United States $0.642B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.413B 0.00
Assembly Biosciences (ASMB) United States $0.397B 0.00
Akorn (AKRX) United States $0.375B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.200B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.172B 0.00
Sol-Gel Technologies (SLGL) Israel $0.137B 0.00
Acasti Pharma (ACST) Canada $0.072B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.062B 0.00
Agile Therapeutics (AGRX) United States $0.061B 0.00
Teligent (TLGT) United States $0.047B 0.00
China Pharma Holdings (CPHI) China $0.015B 0.00
Aevi Genomic Medicine (GNMX) United States $0.014B 0.00
Evoke Pharma (EVOK) United States $0.013B 0.00